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Homocysteine (HCY) is an endogenous redox active amino acid, best known as
contributor to various neurodegenerative disorders. Although it is known that HCY
can activate NMDA receptors (NMDARs), the mechanisms of its action on receptors
composed of different NMDA receptor subunits remains almost unknown. In this study,
using imaging and patch clamp technique in cultured cortical neurons and heterologous
expression in HEK293T cells we tested the agonist activity of HCY on NMDARs
composed of GluN1 and GluN2A subunits (GluN1/2A receptors) and GluN1 and
GluN2B subunits (GluN1/2B receptors). We demonstrate that the time courses of Ca2+
transients and membrane currents activated by HCY and NMDA in cortical neurons
are drastically different. Application of HCY to cortical neurons induced responses,
which in contrast to currents induced by NMDA (both in the presence of glycine)
considerably decreased to steady state of small amplitude. In contrast to NMDA, HCY-
activated currents at steady state were resistant to the selective GluN2B subunit inhibitor
ifenprodil. In calcium-free external solution the decrease of NMDA evoked currents
was abolished, suggesting the Ca2+-dependent NMDAR desensitization. Under these
conditions HCY evoked currents still declined almost to the baseline suggesting Ca2+-
independent desensitization. In HEK293T cells HCY activated NMDARs of GluN1/2A
and GluN1/2B subunit compositions with EC50s of 9.7 ± 1.8 and 61.8 ± 8.9 µM,
respectively. Recombinant GluN1/2A receptors, however, did not desensitize by HCY,
whereas GluN1/2B receptors were almost fully desensitized by HCY. Thus, HCY is a
high affinity agonist of NMDARs preferring the GluN1/2A subunit composition. Our data
suggest that HCY induced native NMDAR currents in neurons are mainly mediated by
the “synaptic type” GluN1/2A NMDARs. This implies that in hyperhomocysteinemia,
a disorder with enlarged level of HCY in plasma, HCY may persistently contribute to
post-synaptic responses mediated by GluN2A-containing NMDA receptors. On the
other hand, HCY toxicity may be limited by desensitization typical for HCY-induced
activation of GluN2B-containing extrasynaptic receptors. Our findings, therefore, provide
an evidence for the physiological relevance of endogenous HCY, which may represent
an effective endogenous modulator of the central excitatory neurotransmission.
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INTRODUCTION
L-Homocysteine [2-amino-4-sulfanylbutanoic acid (HCY)] is
an endogenous sulfur-containing amino acid involved in
synthesis of methionine and cysteine. The normal HCY level
in plasma is generally below 16 µM (Shi et al., 2003).
However, a deficit of folic acid and vitamins B or the C677T
polymorphism of the 5′-10′-methylenetetrahydrofolate reductase
gene (a substitution of cytosine for thymine at position 677,
C677T) can cause an elevation of HCY level (a condition
known as hyperhomocysteinemia, Kowa et al., 2000). High
level of HCY have been proposed to contribute to a variety
of cardiovascular and neurodegenerative disorders, such as
Alzheimer’s and Parkinson’s disease (Kuhn et al., 2001; Kruman
et al., 2002; Sachdev, 2005) as well as amyotrophic lateral
sclerosis (Zoccolella et al., 2010). Recent data implicate the
C677T polymorphism in the pathogenesis of migraine with aura
(Moschiano et al., 2008; Lea et al., 2009; Oterino et al., 2010). We
previously showed that the high level of HCY led to the neuronal
death through activation of NMDA receptors (NMDARs) and
mGluR5 (Abushik et al., 2014).
Several studies reported that HCY (Lipton et al., 1997;
Ganapathy et al., 2011; Bolton et al., 2013), as well as its
derivative, homocysteic acid, studied earlier (Provini et al., 1991;
Kilic´ et al., 1992) is an agonist operating via the glutamate
binding sites of the NMDARs. In addition, HCY at relatively high
concentrations (above 1 mM HCY) can compete with glycine
for the NMDAR co-agonist binding sites (Lipton et al., 1997).
Recently, effects of HCY at relatively high concentrations (up to
1 mM) on NMDA and glutamate activated currents transferred
through the channels of recombinant NMDARs composed of
the GluN1 and GluN2A, GluN1 and GluN2B or GluN1 and
GluN2D subunits were studied (Bolton et al., 2013). It has
been demonstrated, that HCY can differently modulate peak
amplitude of currents activated by NMDA and glutamate and
reduce NMDAR desensitization caused by NMDA and glutamate
depending on GluN2 subunit compositions (Bolton et al., 2013).
Thus, several groups suggested that neuronal NMDARs may
represent an important target for the action of elevated HCY
(Kim and Pae, 1996; Lipton et al., 1997; Ganapathy et al.,
2011; Poddar and Paul, 2013). Nevertheless, the specific features,
associated with the action of HCY on NMDARs composed of
the “synaptic type” GluN2A subunit and the “extrasynaptic type”
GluN2B subunit are still missing.
An accumulation of HCY in the cerebrospinal fluid
mentioned above is associated with severe pathologies and
dysfunctions of the human central nervous system. As a wide
population of patients suffers from hyperhomocysteinemia, a
new knowledge of the precise receptor mechanisms of neuronal
HCY effects may potentially improve a therapeutic strategy of
these diseases. In addition, a discrepancy in mechanisms, by
which HCY activates NMDARs composed of different GluN2
subunits may provide important information for NMDAR
physiology. Therefore, in order to clarify subunit-specific
properties of HCY action on NMDARs we studied its effects
on native NMDARs in rat cortical neurons and recombinant
GluN1/2A and GluN1/2B receptors expressed in HEK293T cells.
Here, we report that GluN2A subunit-containing NMDARs
represent the preferential targets for HCY and mainly contribute
to neuronal pathogenesis during hyperhomocysteinemia through
activation of synaptic GluN1/2A receptors.
MATERIALS AND METHODS
Primary Culture of Cortical Neurons
The procedure of culture preparation from rat embryos was
previously described (Antonov et al., 1998; Mironova et al.,
2007). All procedures using animals were in accordance with
recommendations of the Federation for Laboratory Animal
Science Associations and approved by the local Institutional
Animal Care and Use Committees. Wistar rats (provided by the
Sechenov Institute’s Animal Facility) 16 days pregnant (overall
12 animals in this study) were sacrificed by CO2 inhalation.
Fetuses were removed and their cerebral cortices were isolated,
enzymatically dissociated, and used to prepare primary neuronal
cultures. Cells were used for experiments after 10–15 days in
culture (Mironova et al., 2007; Han and Stevens, 2009). Cells
were grown in NeurobasalTM culture medium supplemented
with B-27 (Gibco-Invitrogen, UK) on glass coverslips coated with
poly-D-lysine.
HEK293T Cells with Recombinant
NMDAR
Human embryonic kidney (HEK) 293T cells were maintained
as previously described (Qian et al., 2005). HEK293T cells were
plated onto 7 mm glass coverslips pretreated with poly-L-lysine
(0.2 mg/ml) in 35 mm culture dishes at 1 × 105 cells per dish.
18–24 h after plating cells were transiently transfected with a
pcDNA1 plasmid encoding either rat NMDA receptor subunit
GluN2A or GluN2B, and pcDNA3.1 plasmids encoding GluN1
and EGFP using FuGene HD reagent (Promega, Madison, WI,
USA). Briefly, transfection was performed by adding to each
dish 50 µl serum-free medium containing 1 µg total DNA and
2 µl FuGene. The ratio of cDNA used was 1 EGFP: 1 GluN1:
3 GluN2 (A or B). After incubation of cells for 6–8 h the
transfection solution was replaced with fresh culture medium
containing 200 µM DL-2-amino-5-amino-5-phosphono-valeric
acid (DL-AP-5) and 2 mM Mg2+ to prevent NMDA receptor
mediated-excitotoxicity. Experiments were performed 24–72 h
after transfection. Mammalian expression vectors were supplied
by Dr. J. W. Johnson (University of Pittsburgh, Pittsburgh, PA,
USA).
Patch Clamp Recordings
Whole-cell patch clamp recordings of membrane currents
were performed on cultured rat cortical neurons (10–15 DIV)
and HEK293T cells expressing recombinant GluN1/2A or
GluN1/2B receptors. We used a MultiClamp 700B patch-clamp
amplifier with Digidata 1440A acquisition system controlled
by pClamp v10.2 software (Molecular Devices, Sunnyvale, CA,
USA). The signal was 8-order low-pass Butterworth filtered at
200 Hz to remove high frequency noise. Acquisition rate was
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20000 s−1. Micropipette positioning was made with an MP-85
micromanipulator (Sutter Instrument, Novato, CA, USA) under
visual control using a Nikon Diaphot TMD microscope (Nikon,
Japan). For fast medium exchange we used a BPS-4 fast perfusion
system (ALA Scientific Instruments, Farmingdale, NY, USA).
The tip of the multichannel manifold was placed at a distance
of 0.2 mm from the patched cell, allowing solution exchange
in 80 ms. Unless otherwise specified the following extracellular
medium was used for recording (external bathing solution, in
mM): 140 NaCl; 2.8 KCl; 1.0 CaCl2; 10 HEPES, at pH 7.2–
7.4. Patch-pipette solution had the following composition (in
mM): 120 CsF, 10 CsCl, 10 EGTA, and 10 HEPES. The pH
was adjusted to 7.4 with CsOH. Measured osmolarities of the
external bathing solution and the patch-pipette solution were
310 and 300 mOsm, respectively. Patch pipettes (2–4 M) were
pulled from 1.5-mm (outer diameter) borosilicate standard wall
capillaries with inner filament (Sutter Instrument, Novato, CA,
USA). Experiments were performed at room temperature (23–
25◦C). In whole-cell configuration the series resistances did
not exceed 10 M. After correction for the liquid junction
potential between the Na+-containing external bathing solution
and the Cs+-containing pipette solution of −15 mV the default
membrane voltage (Vm) was set to −55 mV for neurons and
−35 mV for HEK293T cells. Functional activity of NMDARs
requires binding of both glutamate and a co-agonist, glycine.
Unless otherwise stated, to activate NMDARs we applied 50 µM
L-HCY (HCY) or 30 µM NMDA with 30 µM L-glycine
(Gly).
Loading of Fluo-3 AM and Ca2+ Imaging
Cells were loaded with Fluo-3 AM (4 µM, Life Technologies,
Foster City, CA, USA) using conventional protocols as
recommended by the manufacturer. In brief, neuronal cultures
were incubated with Fluo-3 AM for 45 min in the dark at
room temperature. Then, Fluo-3 AM was washed out, and cells
were incubated in the external solution for another 30 min in
the dark. Coverslips with Fluo-3-loaded cultures were placed in
the perfusion chamber, which was mounted on the stage of a
Leica TCS SP5 MP inverted microscope (Leica Microsystems,
Germany). Fluorescence was activated with 488 nm laser light
and emission was measured within the wavelength range from
500 to 560 nm. Images were captured every minute during
60 min experiments. In Ca2+ imaging experiments to activated
NMDARs 100 µM DL-HCY and 30 µM Gly were used.
Drugs
Compounds were from Sigma-Aldrich, St. Louis, MO, USA.
Data Analysis
Quantitative data are expressed as mean ± SEM. ANOVA and
Bonferroni multiple comparison methods as well as Student’s
two-tailed t-test were used for statistical analysis. Number
of experiments is indicated by n throughout. The data were
considered as significantly different based on a confidence level
of 0.05. Current measurements were plotted using ClampFit
10.2 (Molecular Devices). The EC50 (half-maximal effective
concentration for HCY as an agonist) and Hill coefficient (h) were
estimated by fitting of concentration-response curves with the
Hill equation, I[HCY]/Imax = 1/(1 + EC50h/[HCY]h), where the
Imax is the current of maximal amplitude elicited by HCY and
I[HCY] are the current amplitudes measured at each [HCY].
RESULTS
Amplitude and Dynamic Difference of
Neuronal Responses to HCY and NMDA
As the starting point for evaluation of agonist properties of
HCY, we compared intracellular Ca2+ responses ([Ca2+]i)
elicited by NMDA and HCY in non-patched cortical neurons.
Figure 1A shows that application of 100 µM DL-HCY induced
fast Ca2+ responses, which quickly decayed to the baseline
and often were followed by small repetitive waves. In contrast,
application of 30 µM NMDA activated typical sustained [Ca2+]i
responses of comparable amplitude, that lasted as long as
NMDA was present (Figure 1A). As the [Ca2+]i increase could
be determined by Ca2+ entry through the NMDARs, voltage
gated calcium channels, and/or Ca2+ release from intracellular
stores, we next explored the action of HCY using patch
clamp technique. Consistent with the different shape of Ca2+
responses, membrane currents activated by 50 µM HCY differed
from currents activated by 30 µM NMDA, both in amplitude
and time course. Although in some cells, HCY and NMDA
activated currents of comparable peak amplitude (Figure 1B,
top), the average peak amplitude of currents activated by HCY
was significantly less than of currents activated by NMDA
(Figure 1C). However, the most notable difference was the
relative level of the steady-state currents. Figure 1D demonstrates
that the ratio of steady-state amplitudes to peak amplitudes was
significantly smaller for HCY activated currents than for NMDA
activated currents. In almost all cases the steady-state current
amplitude was much lower when activated by HCY than when
activated by NMDA (Figures 1B,C). Thus, both Ca2+-imaging
and patch clamp recording data uncovered essential differences
between the actions of HCY and NMDA on native NMDARs in
cortical neurons.
Pharmacological Features of Neuronal
Responses to HCY
We further compared pharmacological characteristics of currents
activated by HCY and NMDA. An antagonist of mGluR5, 3-
((2-methyl-4-thiazolyl)ethynyl)pyridine (MTEP), did not affect
HCY-induced currents under experimental conditions used here,
suggesting that activation of mGluR5 does not contribute to
the currents activated by HCY (data not shown). Competitive
antagonist of NMDARs (2R)-amino-5-phosphonopentanoate
(AP-5), caused almost complete block of HCY-induced currents
(Figures 2A,D) suggesting that the currents were indeed
transferred through the NMDAR channels. Notably, the currents
activated by HCY at steady state were resistant to the action
of ifenprodil (Figures 2B,D). In contrast, this GluN2B subunit
selective inhibitor (Williams, 1993) efficiently blocked currents
activated by NMDA (Figures 2C,D).
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FIGURE 1 | Comparison of neuronal responses to NMDAR agonists. (A) Ca2+ responses induced by 100 µM DL-HCY and 30 µM NMDA in the presence of
30 µM Gly applied for 2 min to neurons loaded with Fluo-3 AM. Traces represent an overlay of neuronal responses (four neurons). Application protocol is shown
above the traces. (B) Whole-cell currents activated in neurons by application of 50 µM HCY and 30 µM NMDA in the presence of 30 µM Gly recorded at
Vm = −55 mV. (C) Quantitative comparison of peak amplitudes of currents activated by 50 µM HCY and 30 µM NMDA in the presence of 30 µM Gly recorded from
the same neurons (n = 57) at Vm = −55 mV during paired agonist applications. Data differ significantly (∗∗∗p < 0.0001, two-tailed Student’s t-test). (D) Quantitative
comparison of steady-state amplitude (Iss) to peak amplitude (Ipeak ) ratios of currents activated by HCY and NMDA during paired applications. Data differ significantly
(∗∗∗p < 0.0001, two-tailed Student’s t-test).
Taken together, these experiments demonstrated considerable
pharmacological differences between NMDA and HCY as
agonists of NMDARs.
NMDAR Desensitization Induced by
NMDA and HCY in Neurons
Since different agonists of NMDARs can induce NMDAR
desensitization of different onset and offset rates (Lester and Jahr,
1992), we further studied desensitization of NMDARs caused by
NMDA and HCY in cortical neurons.
Currents activated by NMDA declined to a steady-state
level because of receptor desensitization (Figure 3A). The time
constant of desensitization onset (τon) was measured by fitting
the decay of NMDAR mediated currents to steady state with a
single exponential function (Figure 3A). In the presence of Ca2+
in the external bathing solution the τon value for NMDA induced
currents was 1.6± 0.1 s (n= 36).
In the case of HCY, currents also declined to the steady-state
level (Figure 3B). The τon for HCY was 1.6 ± 0.2 s (n = 47) and
did not differ significantly from NMDAR desensitization caused
by NMDA (p> 0.8, Student’s two-tailed t-test, Figure 3C).
In Ca2+-free external bathing solution, however, the currents
activated by NMDA did not decrease in time, revealing the
lack of desensitization (Figures 3A,D). In sharp contrast, the
onset of desensitization caused by HCY remained unchanged
(τon = 1.2 ± 0.2 s, n = 34, Figures 3B–D). These data
demonstrated that NMDA-induced responses were characterized
by Ca2+-dependent desensitization (Legendre et al., 1993; Zhang
et al., 1998; Sibarov et al., 2015), whereas desensitization of
HCY-induced responses was almost Ca2+-independent.
In order to estimate the time constant of recovery from
desensitization induced by NMDA and HCY for native NMDARs
we used a double application protocol consisting of 4–12 repeats.
In this protocol, the second application of the agonists in the
next repeat was applied with an incrementing delay of 1–2 s
from the first. The increment duration was chosen to achieve a
best resolution of the desensitization offset (Figures 4A,B). The
recovery from desensitization was measured as an increase of
current amplitudes in the sequence of second agonist applications
which was well-fitted by a single exponential function with a time
constant (τoff) of the desensitization offset (Figure 4C). Whereas,
the τon values of the native NMDAR desensitization onset caused
by NMDA and HCY were similar (Figure 3C), the τoff value for
NMDA elicited currents was significantly larger, than those for
HCY (p < 0.0001, Student’s two-tailed t-test) and were 6.3 ± 1.1
(n= 6) and 2.5± 0.5 s (n= 5), respectively (Figure 4C).
The removal of Ca2+ from the external bathing solution
nearly abolished the amplitude decrease of NMDA-activated
currents (Figure 4D) demonstrating the Ca2+ dependence of
NMDAR desensitization. In contrast the decrease of currents
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FIGURE 2 | Pharmacological properties of neuronal currents activated by HCY and NMDA. (A) Representative current trace recorded in a neuron at
Vm = −55 mV activated by 50 µM HCY + 30 µM Gly. After current reached steady state, 100 µM AP-5 was applied. The application protocol is shown above the
trace. (B) Representative current trace recorded in a neuron at Vm = −55 mV activated by 50 µM HCY + 30 µM Gly. After current reached steady state, 5 µM
ifenprodil (ifen) was applied. The application protocol is shown above the trace. (C) Representative current trace recorded in a neuron at Vm = −55 mV activated by
30 µM NMDA + 30 µM Gly. After current reached steady state, 5 µM ifenprodil (ifen) was applied. The application protocol is shown above the trace. (D)
Quantitative comparison of inhibition of NMDA-activated currents caused by 5 µM ifenprodil (ifen, n = 18) and 100 µM AP-5 (n = 24) and inhibition of HCY-activated
currents caused by 5 µM ifenprodil (ifen, n = 26) and 100 µM AP-5 (n = 9). Ordinate axis – ratio of the current amplitude obtained during inhibition (Iin) to the
steady-state current amplitude (Iss) obtained without antagonists. Data differ significantly from steady-state current control amplitudes (∗∗∗p < 0.0006, ANOVA, post
hoc Bonferroni test).
activated by HCY remained unchanged (Figure 4E) in the Ca2+-
free media suggesting that native NMDAR desensitization evoked
by HCY is not Ca2+- dependent. Moreover, the τoff value of HCY
induced desensitization (τoff = 2.7 ± 0.7 s, n = 4, Figure 4F)
obtained in the Ca2+-free media was similar to the τoff value
found in the presence of Ca2+ in the external bathing solution
(τoff = 2.5 ± 0.5 s, n = 5, Figure 4C) and did not differ
significantly (p> 0.85, Student’s two-tailed t-test).
Overall, the above experiments reveal substantial kinetic,
amplitude, and pharmacological differences between currents
activated by NMDA and HCY in cortical neurons as well
as specific properties of desensitization with respect to Ca2+
dependence of this phenomenon.
HCY Induces Fast Desensitization of
Recombinant GluN1/2B NMDARs
Because cortical neurons in primary culture typically express
NMDARs of GluN1/2A and GluN1/2B subunit compositions
(Zhong et al., 1994; Mizuta et al., 1998) we hypothesized that
HCY when activates these receptor subtypes may causes different
kinetics of activation and desensitization.
To get more clues in the mechanism of HCY activation
of NMDARs, we performed experiments on recombinant
GluN1/2A and GluN1/2B receptors expressed in HEK293T cells.
50 µM HCY applied to cells expressing diheteromeric GluN1/2A
receptors caused robust inward currents, which did not reveal
decrease of amplitude during 10 s applications, suggesting a lack
of GluN1/2A receptor desensitization (Figure 5A). Application
of 100 µM Glu (a saturating concentration for GluN1/2A
receptor, see Traynelis et al., 2010), induced currents which were
similar in amplitude to those activated by HCY (Figure 5B).
In the case of Glu, these currents largely decreased to steady
state because of the receptor desensitization (Figure 5A). For
GluN1/2A receptors, the application of 30 µM NMDA induced
currents that were much smaller than those activated by HCY
or Glu. Mean amplitude of NMDA activated currents differed
from mean amplitudes of HCY and Glu activated currents
significantly (p < 0.0001, ANOVA, post hoc Bonferroni test,
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FIGURE 3 | Desensitization of native NMDARs caused by NMDA and HCY. (A) Currents activated by 30 µM NMDA + 30 µM Gly in neurons recorded at
Vm = −55 mV in the presence and absence of Ca2+ in the external bathing solutions. Dotted lines represent fits of a single exponential function to current decays.
(B) Currents activated by 50 µM HCY + 30 µM Gly in neurons recorded at Vm = −55 mV in the presence and absence of Ca2+ in the external bathing solutions.
Dotted lines represent fits of single exponential function to current decays. (C) Quantitative comparison of NMDAR desensitization onsets evoked by NMDA and
HCY in the presence and absence of Ca2+ in the external bathing solution. τon was measured as the time constant of current decay to the steady-state level. Data
do not differ (p > 0.36, ANOVA, n = 10). (D) Quantitative comparison of NMDAR desensitization evoked by NMDA and HCY in the presence and absence of Ca2+
in the external bathing solution. Ordinate axis – ratio of amplitudes obtained at steady-state (Iss) and peak (Ipeak) current as a measure of desensitization. Values differ
significantly from data, obtained with HCY (∗∗∗p < 0.001, ANOVA, post hoc Bonferroni test, n varied from 16 to 56 for different data sets).
n= 37, Figures 5A,B), because of the NMDA concentration used
in these experiments is much smaller than a saturating one. The
data obtained with Glu and NMDA are consistent with known
efficacy and EC50 of Glu and NMDA as agonists of GluN1/2A
NMDARs (for review, see Traynelis et al., 2010).
In contrast to GluN1/2A receptors, applications of 50 µM
HCY to cells expressing diheteromeric GluN1/2B receptors
caused currents that initially peaked and then declined to steady
state of small amplitude (Figure 5C). 100 µM Glu and 30 µM
NMDA induced large GluN1/2B mediated currents (Figure 5C)
that did not differ significantly in their steady-state amplitudes
(Figure 5D). The steady-state current amplitudes achieved
during applications of HCY were very small in comparison
to currents obtained in the presence of Glu and NMDA and
differed from them significantly (p < 0.0001, ANOVA, post hoc
Bonferroni test, n = 57). The data obtained with respect to Glu
and NMDA are consistent with the known efficacy and EC50
of these agonists to binding sites on GluN1/2B NMDARs (for
review, see Traynelis et al., 2010).
Thus, HCY is an effective agonist of NMDARs of both
GluN1/2A and GluN1/2B subunit compositions. GluN1/2A
receptors, however, do not exhibit desensitization during
activation by HCY, whereas the activation of GluN1/2B receptors
by HCY was accompanied by fast and close to complete
desensitization.
HCY as High Affinity Agonist of
Recombinant GluN1/2A NMDARs
In further experiments, we measured the potency (EC50
values) for activation of HCY currents mediated by native
and recombinant GluN1/2A and GluN1/2B NMDARs. First, a
saturating concentration of HCY in the presence of 30 µM Gly
was applied to neurons or HEK293T cells expressing GluN1/2A
and GluN1/2B NMDARs. Then the HCY concentration was
decreased until currents could not be activated (Figure 6A).
For each of NMDAR type the progressive lowering of HCY
concentration caused a decrease of NMDAR current amplitude
measured at steady state (Figure 6A). The dependence of the
steady-state current amplitude on HCY concentration is shown
in Figure 6B. Fits of the Hill equation to the data revealed the
apparent dissociation constants (EC50) for HCY with NMDARs
and the Hill coefficients (h) which were 14.4 ± 1.3 µM and
h = 1.8 ± 0.8 (n = 6) for native NMDARs, 9.7 ± 1.8 µM
and h = 1.6 ± 0.5 (n = 10) for GluN1/2A receptors, and
61.8 ± 8.9 µM and h = 2.1 ± 0.3 (n = 10) for GluN1/2B
receptors. Whereas, the HCY EC50 values for GluN1/2A and
native receptors do not differ significantly, they are significantly
smaller than the EC50 value for GluN1/2B receptors (p< 0.0001,
ANOVA, post hoc Bonferroni test, Figure 6C). Therefore, HCY
can be considered a high potency agonist of NMDARs composed
by the GluN1/2A subunits. The similarity between the HCY
EC50 values obtained on the native and GluN1/2A NMDARs,
may suggest that the currents, activated by HCY in neurons, at
the steady state are predominantly mediated by diheteromeric
GluN1/2A NMDARs.
DISCUSSION
The main finding of this study is that the endogenous amino
acid, HCY, implicated in various brain diseases preferentially
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FIGURE 4 | Recovery from desensitization induced by NMDA and HCY. (A) An overlay of currents activated by 30 µM NMDA + 30 µM Gly using the paired
application protocol (shown above the traces) recorded in the neuron at Vm = −55 mV in the presence of Ca2+ in the external bathing solution. (B) An overlay of
currents activated by 50 µM HCY + 30 µM Gly using the paired application protocol (shown above the traces) recorded in the neuron at Vm = −55 mV in the
presence of Ca2+ in the external bathing solution. (C) The dependence of the peak current amplitude achieved during the second agonist application on the
duration of delay between applications. Ordinate axis – ratio of the peak amplitudes of the current elicited by the second application (I2) to the current elicited by the
first application (I1). The peak amplitude of currents activated by the first application was taken for 100%. Open circles – the data obtained by NMDA applications
(n = 6 for each point). Filled circles – the data obtained by HCY applications (n = 5 for each point). Lines represent fits of a single exponential function to the data
points. (D) An overlay of currents activated by 30 µM NMDA + 30 µM Gly using the paired application protocol (shown above the traces) recorded in the neuron at
Vm = −55 mV in Ca2+-free media. (E) An overlay of currents activated by 50 µM HCY + 30 µM Gly using the paired application protocol (shown above the traces)
recorded in the neuron at Vm = −55 mV in Ca2+-free media. (F) The dependence of the peak current amplitude achieved during the second agonist application on
the duration of delay between applications. Ordinate axis – ratio of the peak amplitudes of the current elicited by the second application (I2) to the current elicited by
the first application (I1). The peak amplitude of currents activated by the first application was taken for 100%. Open circles – the data obtained by NMDA applications
(n = 6 for each point). Filled circles – the data obtained by HCY applications (n = 4 for each point). Lines represent fits of a single exponential function to the data
points.
activates “synaptic type” GluN2A subunit-containing NMDA
receptors with specific kinetics properties including limited
receptor desensitization.
HCY Signaling in Brain
Homocysteine that accumulates in plasma during hyperhomo-
cysteinemia can potentially lead to the death of cortical neurons
(Lipton et al., 1997; Abushik et al., 2014), retinal ganglion cells
(Ganapathy et al., 2011) and trigeminal neurons (Abushik et al.,
2014). This type of excitotoxicity is likely mediated by activation
of native NMDARs (Lipton et al., 1997; Ganapathy et al., 2011;
Bolton et al., 2013; Abushik et al., 2014).
The goal of our study was to clarify the mechanism of HCY
action on cortical neurons. In order to succeed in addressing
this goal, we compared HCY action on recombinant NMDARs
of known composition. GluN1/2A and GluN1/2B receptors in
different regions of adult brain exhibit preferentially synaptic
and extrasynaptic locations, respectively, which are subjected
for activity-dependent modulation and may change during
pathogenesis (Paoletti et al., 2013). Notably, cortical neurons
vary substantially with respect to GluN2A versus GluN2B
expression ratio (Tovar and Westbrook, 1999; Traynelis et al.,
2010). Our data in general are consistent with the view that
HCY is an agonist of NMDAR glutamate binding sites (Lipton
et al., 1997; Ganapathy et al., 2011; Bolton et al., 2013).
This would suggest that neuronal responses of NMDARs to
HCY, Glu or NMDA used at equally potent concentrations
should have similar amplitudes and time courses. However,
in this study we found that HCY-induced intracellular Ca2+
responses as well as NMDAR-mediated currents differ greatly
with respect to their amplitudes and time courses from responses
to NMDA obtained on the same neurons. In contrast to NMDA,
which activated sustained Ca2+ intracellular responses, HCY
induced fast oscillatory intracellular Ca2+ transients which
peaked and than briefly declined to the control [Ca2+]i. Currents
activated by HCY also varied greatly by amplitudes between
neurons, being generally much smaller (on average about 1/6),
than the corresponding NMDA induced currents. Moreover,
pharmacological analysis indicated that the steady-state currents,
activated by HCY, were resistant to ifenprodil, a GluN2B selective
inhibitor of NMDARs (Williams, 1993). Most striking, unlike
Ca2+-dependent NMDA-induced desensitization, the NMDAR
desensitization evoked by HCY did not depend on extracellular
Ca2+. Thus, Ca2+-independent HCY desensitization could be
defined as a ligand-dependent NMDAR desensitization (Lester
and Jahr, 1992).
Taken together, these observations suggest that neuronal
NMDAR currents, transferred through channels of GluN1/2A
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FIGURE 5 | Comparison of currents activated by HCY in HEK293T cells expressing recombinant GluN1/2A and GluN1/2B receptors. (A) Currents
activated by 50 µM HCY, 100 µM Glu, and 30 µM NMDA in the presence of 30 µM Gly recorded in HEK293T cells at Vm = −35 mV expressing NMDARs of
GluN1/2A subunit compositions. (B) Histogram of the steady-state amplitudes of currents activated by these agonists in the same cells. The data are significantly
different (∗∗∗p < 0.0001, ANOVA, post hoc Bonferroni test, n = 37). (C) Currents activated by 50 µM HCY, 100 µM Glu, and 30 µM NMDA in the presence of
30 µM Gly recorded in HEK293T cells at Vm = −35 mV expressing NMDARs of GluN1/2B subunit compositions. (D) Histogram of the steady-state amplitudes of
currents activated by these agonists in the same cells. The data are significantly different (∗∗∗p < 0.0001, ANOVA, post hoc Bonferroni test, n = 57).
and GluN1/2B receptors, have very different kinetics and
pharmacological sensitivity when activated by HCY and NMDA.
Role of Subunit Composition
Our experiments on recombinant GluN1/2A and GluN1/2B
NMDARs expressed in HEK293T cell disclosed the peculiarities
of complex desensitization kinetics when native NMDARs were
activated by HCY and NMDA. We found that HCY is a high
potency agonist (EC50 is about 9 µM) of GluN1/2A receptors.
Remarkably, during HCY activation these receptors do not
undergo desensitization. In contrast to GluN1/2A receptors,
HCY is a low potency agonist of GluN1/2B receptors (EC50 is
about 70 µM). Furthermore, HCY promotes fast desensitization
of GluN2B-containing receptors providing a low-level steady-
state current. Recently, effects of HCY on currents activated by
NMDA and Glu mediated by different recombinant NMDARs
(containing GluN2A or GluN2B or GluN2C) were studied
(Bolton et al., 2013). In agreement with our study the HCY
effects appeared to be dependent on GluN2 subunits, suggesting
deviations of the HCY effects on different GluN2. Indirectly this
observation supports conclusions drown here.
Our data may allow plausible explanation of peculiarities
in HCY action that determine amplitude and shape of native
NMDAR currents in cortical neurons (Figure 7). Both subtypes
of NMDARs contribute to currents activated by NMDA
(Figure 7A) and, most likely, to the peak current activated
by HCY. In case of HCY the peak current declines quickly
because of the GluN1/2B receptor desensitization caused by
HCY. Therefore, GluN1/2B receptors can contribute little to
depolarization and Ca2+ transients induced by HCY in neurons
during long-lasting periods of action (Figure 7B). As a result the
steady-state currents activated in neurons by HCY are generally
transferred through the channels of GluN1/2A receptors, which
do not undergo desensitization. Our observation that HCY
activated currents at steady state are resistant to ifenprodil is
consistent to this explanation. In addition, because the GluN1/2B
versus GluN1/2A expression ratio varies substantially between
neurons the amplitudes of peak and steady-state components
of currents activated by HCY could demonstrate considerable
variability.
Pathophysiological Implications
The data predict that HCY may have different neuronal
targets depending on NMDAR subunit compositions. One
major distinction between the two receptor subtypes is that
the GluN2A-containing NMDARs are thought to occur in
post-synaptic regions and have exclusively synaptic location
(Tovar and Westbrook, 1999; Momiyama, 2000; Steigerwald
et al., 2000; Dalby and Mody, 2003; de Armentia and Sah,
2003, see also Figure 7). In opposite, NMDARs, which are
supposed to contain the GluN2B subunit, are distributed over
large extrasynaptic somatic and dendritic areas and mediate the
synaptic cross talk sensing the neurotransmitter spillover during
excessive synaptic activity (Scimemi et al., 2004). Interestingly,
GluN2A- and GluN2B-containing NMDARs have been linked
to different intracellular cascades contributing in LTP and LTD
and also leading to preferential triggering neuroprotection and
neurodegeneration, respectively (Hardingham and Bading, 2010;
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FIGURE 6 | Measurements of EC50 for HCY as an agonist of native NMDARs and recombinant NMDARs of GluN1/2A and GluN1/2B subunit
compositions. (A) Currents elicited by the indicated HCY concentrations in the presence of 30 µM Gly recorded in cortical neurons at Vm = −55 mV and in
HEK293T cells expressing recombinant GluN1/2A and GluN1/2B NMDARs at Vm = −35 mV. Application protocols are indicated above the records. (B)
Concentration-activation curves for HCY obtained for currents mediated by native NMDARs (filled squares) and recombinant NMDARs of GluN1/2A (filled circles) and
GluN1/2B (open circles) subunit compositions. Ordinate axis – ratio of amplitudes obtained at steady state in the presence of different HCY concentrations (I[HCY]) to
the maximal amplitude (Imax). Solid lines indicate fits of the data with the Hill equation. (C) Quantitative comparison of EC50s for HCY activation of native and
recombinant GluN2A- and GluN2B-containing NMDARs. Data are significantly different (∗∗∗p < 0.0001, ANOVA, post hoc Bonferroni test, n = 6–10).
FIGURE 7 | Schematics of the data interpretation. (A) During excitotoxic episodes Glu activates both extrasynaptic GluN2B-containng NMDARs and synaptic
GluN2A-containing NMDARs. Entry of external Ca2+ into neurons through open NMDAR channels causes intracellular Ca2+ overload. (B) During
hyperhomocysteinemia HCY desensitizes extrasynaptic GluN2B-containng NMDARs limiting intracellular Ca2+ accumulation in the extrasynaptic regions. Synaptic
GluN2A-containing NMDARs are kept activated by HCY that allows intracellular Ca2+ accumulation in post-synaptic regions and presynaptic terminal inducing
synaptic Ca2+ oscillations.
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Gladding and Raymond, 2011; Stark and Bazan, 2011). Given the
preferential contribution of GluN2A-containing NMDARs to the
HCY effects, this amino acid is expected to be much less efficient
neurotoxicant, than NMDA. In consistence to achieve the similar
levels of apoptosis in primary culture of rat cortical neurons a 24-
h exposure to HCY was required (Abushik et al., 2014), instead of
a 4-h exposure to NMDA (Sibarov et al., 2012). Unlike NMDA-
induced excitotoxicity is sensitive to NMDAR inhibitors (Church
et al., 1988; Mironova et al., 2007), apoptosis caused by HCY
is highly sensitive to the mGluR5 antagonist MTEP (Abushik
et al., 2014). The latter suggests that mGluR5 receptors are
most important players in triggering HCY excitotoxicity, rather
than NMDARs. Based on current observations, we suggest that
HCY preferentially increases the synaptic excitability activating
the GluN2A-containing NMDARs as well as mGluR5 which
can functionally interact with NMDARs at the pre- and post-
synaptic compartments (Sylantyev et al., 2013). In contrast to
the GluN2A-containing NMDARs, the effects mediated by the
GluN2B-containing receptors are expected to be inhibited in
the presence of HCY due to essential desensitization (Figure 7).
This may have some functional consequences interfering with the
development of LTD and affecting the neurotransmitter spillover
(Scimemi et al., 2004).
The range of HCY concentrations that activates the GluN2A-
containing receptors (EC50 about 9 µM) corresponds to the
normal level of endogenous HCY, which varies from 5 to
15 µM in human plasma (Shi et al., 2003). Notably, during
hyperhomocysteinemia the concentration of this amino acid
can rise up to 200 µM (Fritzer-Szekeres et al., 1998) making
it likely that HCY can contribute to persistent (due to low
desensitization) activation of synaptic type NMDARs. Based
on our data, the neurotoxic profiles of NMDA or glutamate
(Figure 7A) and HCY (Figure 7B) should be considerably
different. In excitotoxicity glutamate activates GluN1/2A and
GluN1/2B with similar kinetics and can cause Ca2+ overload
of extrasynaptic as well as synaptic regions of neurons
(Figure 7A). In contrast, in hyperhomocysteinemia HCY
activates synaptic GluN1/2A receptors which may cause Ca2+
accumulation in spines and presynaptic terminals (Figure 7B).
In addition HCY desensitizes mainly extrasynaptic GluN1/2B
receptors, thus limiting Ca2+ accumulation in the extrasynaptic
regions (Figure 7B). Our findings, therefore, provide molecular
mechanisms of HCY neuronal effects and a corroborating
evidence for the physiological relevance of endogenous HCY,
which may allow understanding the role of this amino
acid in modulation of the excitatory neurotransmission and
neurotoxicity.
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